Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts

Aytu BioPharma reported a decrease in net revenue for Q2 2025, reflecting challenges in its ADHD portfolio. Despite this, the company posted a net income of $800,000, translating to $0.13 per share. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculation, though it has faced significant headwinds with a -16.5% decline in the past week. The company’s strategic focus on cost savings and business development is expected to drive future growth.

[Get access to 12+ exclusive InvestingPro Tips for AYTU and discover crucial insights about the company’s financial health and growth potential.]

Key Takeaways

• Net revenue fell to $16.2 million, down from $18.7 million year-over-year.
• ADHD portfolio revenue decreased by 17%, while the pediatric segment showed growth.
• Cost-saving measures include a 37% reduction in G&A expenses over two years.
• Aytu BioPharma aims for positive cash flows and is exploring new business opportunities.

Company Performance

Aytu BioPharma’s Q2 2025 performance reflects a challenging environment, particularly in the ADHD market. The company managed to maintain profitability, with a net income of $800,000. Despite a decline in overall revenue, the pediatric segment showed resilience, growing from $2.1 million to $2.4 million year-over-year. The company continues to leverage its A2RxConnect platform, which supports prescription growth and patient access.

Financial Highlights

• Net Revenue: $16.2 million, down from $18.7 million year-over-year
• ADHD Portfolio Revenue: $13.8 million, a 17% decrease year-over-year
• Pediatric Net Revenue: $2.4 million, up from $2.1 million year-over-year
• Gross Margin: 66%, down from 78% last year
• Net Income: $800,000 ($0.13 per share)
• Cash Balance: $20.4 million, slightly up from $20.1 million

Outlook & Guidance

Aytu BioPharma is targeting $16-17 million in quarterly ADHD revenue and expects continued growth in its pediatric portfolio. InvestingPro data shows analysts maintain a Buy consensus with an $8 price target, suggesting significant upside potential. The company is actively pursuing business development opportunities in the CNS/psychiatry and pediatrics sectors, aiming for positive cash flows. Strategic initiatives include exploring in-licensing and acquisition opportunities to bolster its portfolio.

[Access the full Pro Research Report for AYTU, part of our coverage of 1,400+ US stocks, for expert analysis and actionable insights.]

Executive Commentary

CEO Josh Disbrow emphasized the company’s growth potential, stating, "We absolutely do anticipate growth." He reiterated the focus on the profitable prescription business, noting, "Our focus going forward is on our profitable prescription business." Disbrow also highlighted expectations for revenue and adjusted EBITDA growth.

Risks and Challenges

• Market volatility in the ADHD segment could impact revenue targets.
• Cost management remains crucial as the company navigates reduced margins.
• Dependence on Medicaid coverage expansions poses a regulatory risk.
• Competition in the CNS and pediatric markets could affect growth strategies.
• Macroeconomic pressures may influence consumer spending and prescription trends.

Q&A

During the earnings call, analysts inquired about the company’s confidence in achieving $16-17 million in ADHD quarterly revenue. Management expressed optimism, citing expanded state Medicaid coverage and the antihistamine franchise’s role in driving pediatric growth. The resolution of previous shareholder litigation was also noted as a positive development.

Full transcript - Aytu BioScience Inc (NASDAQ:AYTU) Q2 2025:

Conference Operator: Good day, everyone, and welcome to the Aytu BioPharma Fiscal twenty twenty five Q2 Earnings Call. At this time, all participants have been placed on a listen only mode. If you have any questions or comments during the presentation, you may press It is now my pleasure to turn the floor over to your host, Robert Blum. Sir, the floor is yours.

Robert Blum, Investor Relations, Aytu BioPharma: All right. Thank you very much and good afternoon, everyone. As the operator indicated, during today’s call, we will be discussing Aytu Biopharma’s fiscal twenty twenty five second quarter operational and financial results for the period ended 12/31/2024. Joining us on today’s call is DayTwo’s Chief Executive Officer, Josh Disbrow and Ryan Selhorn, the Company’s Chief Financial Officer. At the conclusion of today’s prepared remarks, we will open the call for a question and answer session.

I’d like to remind everyone that today’s call is being recorded. A replay of today’s call will be available by using the teleconference numbers and conference ID provided in the press release issued earlier today or by utilizing a link on the company’s website under Events and Presentations. Finally, I’d also like to call to your attention the customary Safe Harbor disclosure regarding forward looking information. The conference call today will contain certain forward looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Aytu Biopharma. Although management believes these statements are reasonable based on estimates, assumptions and projections as of today, these statements are not guaranteed of future performance.

Time sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties and other factors, including, but not limited to, the factors set forth in the company’s filings with the SEC. Aytu undertakes no obligation to update or revise any of these forward looking statements. With that said, let me turn the call over to Josh Disbrow, Chief Executive Officer of Aytu Biopharma. Josh, please proceed.

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Thank you, Robert, and welcome, everyone. I’m pleased to be speaking with you again this quarter. During the second fiscal quarter, we successfully returned both our ADHD and pediatric portfolios to positive sequential prescription growth. The first such occurrence in which both portfolios exhibited sequential script growth since late ’twenty two. Our commercial team has done a great job navigating the various dynamics of the macro landscape for our addressable markets, with our sales team increasing physician demand as we also drive improvement in payer coverage and broaden distribution and dispensing.

And we’re doing this while continuing to leverage the benefits of our first in class A2RxConnect platform. I’ll touch more on both our ADHD and pediatric market trends in a moment. This positive commercial momentum runs parallel to our corporate optimization initiatives, driving efficiencies within our operating structure with at least $2,000,000 in future cost savings expected annually. This $2,000,000 in cost savings we recently announced is in addition to the significant OpEx reductions we’re already realizing as a result of the transformation we have undergone in the last two years, inclusive of pausing pipeline spending, discontinuing our consumer health operations and exiting our manufacturing operations. Our focus going forward is on our profitable prescription business and leveraging the unique capabilities of our commercial infrastructure in the A2RxConnect platform, while also pursuing additional in license or acquired products.

I’ll touch more on that as well momentarily. Even before the full realization of all optimization savings takes hold, we reported our seventh consecutive quarter of positive adjusted EBITDA and second consecutive quarter of net income. And we remain on track to drive the business towards positive cash flows. In fact, our cash balance at the December was $20,400,000 which was up slightly from $20,100,000 at the September. All told, I’m very pleased with the continued progress made during the second quarter and the outlook for the rest of the fiscal year.

Let’s jump into the script numbers, trends and outlook for each of our portfolio areas starting with ADHD. For the quarter, scripts for the ADHD portfolio were slightly over $99,000 which compares to just under $99,000 in the first quarter and compared to $111,000 in Q2 of last year. From a top line perspective, ADHD net revenue was $13,800,000 in Q2 compared to $15,300,000 in Q1 fiscal ’twenty five and compared to $16,600,000 in Q2 of last year. We went into great detail last quarter discussing the commercial rebate pickup we had that boosted ADHD net revenue. But I want to once again call this out as it highlights the improvement we saw during this quarter on an apples to apples net revenue basis.

As you’ll likely recall, last quarter, we resolved a multiyear rebate dispute with the payer over unauthorized commercial rebates on our ADHD products, which had previously reduced our net revenue in prior periods and for which we’ve been carrying a gross to net accrual. We resolved that last quarter and the resolution resulted in a one time increase in net revenue of $3,300,000 during the first quarter and a reduction of that liability we have been carrying on our balance sheet for the past few years. If you backed out the $3,300,000 from Q1’s net revenue, ADHD net revenue would have been $11,900,000 So the $13,800,000 we just reported in Q2 on approximately 99,000 scripts compares very favorably with the $11,900,000 in net revenue on also about 99,000 scripts in Q1. So our per script net price actually increased sequentially. ADHD net revenue was up 16% sequentially on an apples to apples basis excluding the one time item.

This highlights an improvement in our gross to net, which given our business model is somewhat to be expected heading into the final quarter of the calendar year. Looking more broadly at the ADHD stimulant market, we continue to see conditions returning to a more normalized state following the series of significant market wide stimulant shortages commencing in early ’twenty three that impacted the supply of products like Adderall XR and other ADHD stimulant meds. As I’ve discussed, fortunately A2 supply was never impacted and we therefore realized some short term and long term benefits from the shortages others were facing. With the market more normalized, the short term benefit we had has made the comps a bit difficult on a year over year basis. But as I mentioned a moment ago, the sequential trends are once again quite positive and we’re above the baseline levels from just a few years ago as many patients that were moved over to Adzenys or Cotempla have stayed on longer term.

I’ll transition now over to the pediatric portfolio. As we’ve communicated for the last few quarters within pediatrics, we were impacted by a variety of payer changes. Initially, we saw the impact when a large payer stopped covering a big portion of pediatric multivitamins affecting the entire multivitamin class. This was exacerbated further as we had some fairly concentrated dispensing areas where this payer has a large market share. Our antihistamine was affected similarly by a payer change in an area where we had a pretty significant concentration of prescribers with that product largely covered by Medicaid.

Fast forward, we’ve been focused on diversifying the prescriber base and improving payer coverage for both franchises, multivitamins as well as with our antihistamine franchise. In particular, we have focused on expanding areas of promotion, diversifying our base of dispensing pharmacies and bringing on several state Medicaid plans that we hadn’t had covering our products before. So as opposed to having all of our eggs in the proverbial one or two baskets, we are in many more states today that are covering our products and this improvement has largely occurred over just the last six or so months. With that, Q2 is really the first quarter that we started to realize the benefits of this improved coverage and access with materially better public and commercial coverage for our pediatric brands. We’ve also deployed sales representatives and shifted resources to our pediatric products.

Previously, pediatric sales were conducted with a much smaller group of sales specialists that focused on promoting these products. We’ve now shifted our sales force’s product mix, providing for better balance and more impactful product penetration, and specifically with increased emphasis on the pediatric products across much of the sales force. As you saw in the press release, we’re seeing dividends already and are very encouraged by our latest Rx and net revenue trends. During Q2, pediatric portfolio net revenue was up 86% sequentially as scripts increased materially. We’re not yet back to where we were a few years ago, but I’m pleased with the positive trends of the last two quarters and the $10,000,000 annualized run rate for these products when you look at this current quarter.

We’re continuing to see good momentum as we again implement on our three key strategies: improve coverage, diversify the base of prescribers and diversify and increase the promotional footprint with the sales force. More broadly, we remain focused on continuing to leverage our flagship best in class patient access platform, A2RxConnect, which we believe is a significant differentiator for the company and one that enables us to stand apart from the competition and truly benefit patients. Indulge me for just a moment to hop on my healthcare ecosystem Soapbox here. In today’s healthcare environment, it’s simply not enough as a pharmaceutical company to go to a prescriber and offer a better clinical solution. You’ve got to solve the entire problem for the patient, which of course includes the clinical benefits, but you absolutely have to solve for the pervasive payer access challenges that impact patients, pharmacies and physicians alike.

Patients today can walk into a neighborhood Walgreens, CVS or Walmart (NYSE:WMT) and frankly have no idea whether they’re going to get the product they were prescribed, if it is going to be received at a timely manner and if and when they can get it, what price they’re going to pay when it comes to an out the door all in cash payment, whether that’s in the form of a co pay, whether they’re paying cash or whatever the case might be. The U. S. Pharmaceutical (TADAWUL:2070) distribution and payment system is very opaque. The market lacks transparency and consistency and that’s where Aytu RxConnect comes in.

This is a proprietary soup to nuts, so to speak, top to bottom program that we’ve developed in house here at Aytu. Its value add protects the dispensing pharmacy, provides confidence to the prescriber, caps patient cash outlays and reduces their hassles and ultimately allows patients to get that branded prescription at an affordable, predictable price. RxConnect involves among other things, a network of about 1,000 pharmacies with whom we work around the country. Most of these are independent pharmacies in local geography that do an excellent job for patients and prescribers and are often well established and well recognized in their respective communities. They’re small businesses that work very hard to serve patients well and go above and beyond and deliver high levels of service for patients.

The other part of our network is two regional grocery chains that are very customer centric, provide excellent service and work directly with us to ensure adequate stocking of our products and to make them more available. So as mentioned, when we sell our products, we obviously sell physicians on the benefits they offer their patients from a clinical standpoint and then equal parts tell them that if they will send these prescriptions to one of these partner pharmacies, they will get the full benefits of RxConnect, which include everything up to including a co pay not to exceed $50 for patients that are commercially insured and when covered the co pay by the way is often zero dollars We essentially underwrite the prescription in cases where it’s not covered or there’s a step edit or a prior authorization that may prevent access. And even in cases where there is a prior authorization, our partners can help obtain that okay, thus taking much of that burden off the physician’s office. This helps the patient first and foremost get the product they were prescribed at a price that’s predictable and affordable. It also helps the physician know that their patient is getting the prescription as prescribed and on time.

As a reminder, these are products that you’re going to take routinely month after month for many, many years potentially for the rest of your life. So it solves this significant issue today where you can walk into your area chain pharmacy and next month you may pay a different price than you paid this month. And that’s the way PBMs have designed it to be opaque and to make it very challenging for patients. And so with RxConnect, we have freed up physicians to prescribe our brands without fear of the dreaded callback from a pharmacy saying either we don’t have it, we can’t get it or even worse, the parent of the patient calling back saying that was a ridiculous, crazy high co pay that was way beyond what I expected or beyond my means. We cut through all of that.

So for the first time with RxConnect, we have put the prescribing power back into the hands of the physicians and the patients. And that’s why with RxConnect, we believe at A2 we can succeed. And for us success is winning for prescribers, for patients and for pharmacies alike. And that’s what we’re working to achieve for these stakeholders every single day. The A2 RxConnect program that envelops our products really is the game changer that enables these products to stand apart.

And we think this will be a key differentiator as we look to the future of our ADHD franchise, our pediatric franchise and dovetails into what the future of A2 has the ability to look like. On that note, as we look at the mid and long term, we first and foremost need to focus on the continued organic growth of our ADHD and pediatric portfolios and cost containment initiatives with a goal of driving towards our goal of positive cash flows. Beyond that, we also expect inorganic growth understanding that Aytu has been built through a series of strategic transactions. Throughout our history, we’ve shown that we are adept at identifying smallest yet valuable assets that maybe don’t fit at a particular organization and have become non strategic. So we see tremendous opportunity to leverage our infrastructure capabilities and expertise and to diversify our portfolio by in licensing or acquiring assets like these.

Of course, we’ll be smart about it and look to pick these assets up as attractively as possible. For now, the appetite is for smallish tuck in assets that we can bolt on and that fit within our commercial footprint and our low cost. And then hopefully as we generate free cash flows, we can also start to look at incrementally larger opportunities in the not too distant future as well. Ultimately, our goal in this area is to continue to bolster the portfolio, diversify the revenue base further and allow us to continue to leverage our high performing commercial infrastructure. Let me now turn the call over to Ryan to review the financials in more details, after which I’ll provide a few closing comments and we can take your questions.

Ryan?

Ryan Selhorn, Chief Financial Officer, Aytu BioPharma: Thank you, Josh. Before we look at the numbers, I want to try to give a big picture overview of where the company stands financially as we enter the calendar 2025 and are more than halfway through our fiscal twenty twenty five year. The company has made huge strides both operationally and financially in the last few years, but it’s still a bit difficult to see our progress because of some of the lingering noise. So if you will indulge me as well, I would like to remind our stockholders and listeners of our achievements over the last few years and provide a glimpse of where we think we can go in the not too distant future. To get to this point, we shuttered our clinical development program, saving $20,000,000 to $30,000,000 in R and D expenditures.

We powered down and ultimately sold off our cash consuming consumer health business. We spent over two years methodically working through the regulatory processes demonstrating bioequivalents of our ADHD brands and ultimately outsourcing the manufacture of these products from our underutilized and expensive Grand Prairie facility. And in conjunction with these things, we continue to cut overhead while still investing in the growth of our business. If you look back just two years ago, for the six months ended 12/31/2022, we incurred $15,300,000 in G and A expenses and today have reported $9,600,000 for the same period in fiscal ’twenty five, a reduction of 37%. Additionally, we incurred sales and marketing expenses for the six months ended 12/31/2022 of $20,700,000 compared with the current six month period of $10,900,000 or a 47% reduction for a combined reduction of $15,500,000 or approximately $31,000,000 annualized.

This represents a reduction across SG and A of 43% on an annualized basis. These strategic changes allowed us to generate positive adjusted EBITDA and keep our cash levels steady, providing us with flexibility and optionality. More importantly, as Josh mentioned, these changes have keyed us up both to grow and ultimately generate free cash flows. The noise I mentioned a moment ago includes things like working through higher cost ADHD inventory manufactured at our now shuttered Grand Prairie facility, one time restructuring expenses related to our optimization, accounting reclassifications and the reinvigoration of our pediatric Rx business. As we continue to work through these items over the next few quarters, our expectations are that we will see ADHD sales once again rise with the market growth, see pediatric sales regain lost sales and build out revenue in new territory, see gross profit margins continue to improve toward the low to mid 70% range, and see operating margins reflect our reduced headcount, leader management structure and outsourced manufacturing.

Let’s now move to the numbers. And please note that our second fiscal quarter financial results are detailed in both our press release and Q2 fiscal twenty twenty five Form 10 Q that we issued earlier today. Our second quarter net revenue was $16,200,000 down from $18,700,000 in the year ago second fiscal quarter. The ADHD portfolio net revenue decreased 17% to $13,800,000 versus $16,600,000 in Q2 fiscal ’twenty four, reflecting normalization of the ADHD stimulant supply chain following more market shortages through much of the fiscal twenty twenty four. On a sequential basis, as Josh touched on, excluding the payer resolution we entered into last quarter, which resulted in a one time increase in our Q1 fiscal twenty twenty five net revenue of $3,300,000 ADHD net revenue increased 16% sequentially.

On the pediatric side, net revenue was $2,400,000 versus $2,100,000 in Q2 of last year. As Josh noted, we are pleased with our pediatric results, which showed a rebound year over year. I will also note that the sequential quarterly numbers are up approximately 86%. This pediatric net revenue improvement demonstrates the continued rebound of the product group from the year ago comparable quarter when the payer changes that impacted Scripps began. The turnaround was first visible last quarter as the sales and marketing programs we implemented gained steam, reflecting both a recapture of lost share and our expansion into new geographies.

Gross margin for the second quarter was 66% compared to 78% in Q2 of last year. As I noted last quarter and just a moment ago, the outsourcing of production out of Grande Prairie to a contract manufacturer is creating noise in the current quarter gross margin, which will most likely continue for the next several quarters. As a reminder, as a part of the switch to contract manufacturing, we needed to reduce our in house production while simultaneously ramping up ADHD production at the contract manufacturer. Unfortunately, this type of manufacturing handoff decreases gross margin on ADHD inventory manufactured in Grand Prairie as fewer units that were manufactured and therefore fewer units had to bear greater amounts of facility and associated overhead costs. Thus, these higher inventory costs now moving through the channel reflect the planned underutilization of Grande Prairie facility as we transition ADHD product manufacturing from inside to outside sourcing.

We anticipate incurring the higher cost of sales until we have sold through this higher cost internally manufactured product. This process is expected to be completed in the coming quarters and the more normalized gross margin should be evident going forward. In addition, we expect gross margins to benefit from the rebound in pediatric sales, which traditionally have carried the highest margins in our product mix. Looking at the quarter’s operating expenses, excluding amortization of intangible assets and restructuring costs, we were down slightly to $10,200,000 from $10,500,000 last year. The decreased operating expenses is a result of the continued cost reduction efforts and the improved operational efficiencies we have discussed.

Please remember that the OpEx number I just mentioned from a year ago excludes this consumer health business as it has been moved to discontinued operations. If you were to look at the actual OpEx from the year ago quarter, the savings are even more pronounced. Put differently, looking at just the G and A on a trailing twelve months basis, excluding the consumer health business, we have enacted over $7,000,000 in savings. On the sales and marketing side, it is an additional $2,500,000 for a total of $9,500,000 in real savings, which ultimately lowers our revenue breakeven level substantially. Net income for the second quarter of fiscal twenty twenty five was $800,000 or $0.13 net income per share basic and $0.26 net loss per share diluted compared to a net loss of $200,000 or $0.04 net loss per share basic and diluted in the prior year period.

The fiscal twenty twenty five second quarter results were impacted by a $3,000,000 of derivative warrant liability gain due primarily to the decrease in the company’s stock price compared to a derivative warrant liability loss of $600,000 in the second quarter of fiscal twenty twenty four. For the quarter, our adjusted EBITDA was a positive $1,300,000 against last year’s quarter of $5,500,000 A major change here is the impact from the gross margins discussed due to the exit of the manufacturing facility as well as the decrease in the ADHD net revenue. A full reconciliation of adjusted EBITDA is included in the press release. Turning now to the balance sheet. Cash and cash equivalents at 12/31/2024, were $20,400,000 compared to $20,100,000 at 09/30/2024.

We continue to maintain our receivables at a healthy level while we look to optimize our inventories via the timely deliveries from our various outsourced manufacturers. On the liability side of

Robert Blum, Investor Relations, Aytu BioPharma: the ledger, we are in

Ryan Selhorn, Chief Financial Officer, Aytu BioPharma: full compliance with all our debt covenants. Also, as a reminder, our term note amortizes monthly, so we continue to pay down our outstanding principal balance, which has decreased to $12,100,000 as of 12/31/2024. As we have commented on periodically, our business’s gross margin percentages can and do vary due to both seasonal and other factors.

Robert Blum, Investor Relations, Aytu BioPharma: I want

Ryan Selhorn, Chief Financial Officer, Aytu BioPharma: to remind all listeners that while we are reviewing the second fiscal quarter twenty twenty five results, we are currently operating in the third fiscal quarter, which of course began January 1 with the new calendar year. Many, if not most plan participants today, as well as the consumers of our products or their parents, have had their annual insurance deductibles reset starting at the beginning of the new year. As such, we expect to experience a greater use of our A2 RS Connect price protection program in Q3 fiscal twenty twenty five, which historically lowers our gross to net margin. Please remember that this value add is part of our normal seasonality and part of our business model. And those growth to net adjustments improve throughout the calendar year as families meet their deductibles and our need to provide the out of pocket backstop subsidies decreases.

With that, let me turn it back over to Josh.

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Thanks, Ryan. Let me just wrap things up by saying that we have successfully implemented a multi year strategic realignment to focus on our profitable prescription business and leverage the unique capabilities of a now streamlined organization. These changes have resulted in the growth of our novel commercialized prescription therapeutics, while also driving positive adjusted EBITDA and approaching profitability. With positive operational trends in place, we remain focused on seeking opportunities to leverage our commercial infrastructure Connect platform while we pursue additional in licensed or acquired products. We continue to expect net revenue and adjusted EBITDA growth from current levels as we strive for positive cash flows.

I’m pleased with the significant progress made and look forward to the continued execution of our strategy in the quarters and years to come. As always, I’d like to thank the entire team at Aytu for their hard work and dedication in delivering for both patients and for stockholders. I’m very proud of the progress that we’ve made collectively. With that, thanks to everyone participating on today’s call. We’ll now be happy to answer any questions.

Conference Operator: Certainly. Everyone at this time, we’ll be conducting a question and answer session. Your first question is coming from Nasr Rahman from Maxim Group. Your line is live.

Nasr Rahman, Analyst, Maxim Group: Hi, everyone. Congrats on the quarter and thanks for taking our questions. I have a few. First, just start on the ADHD franchise. So it looks like the franchise on quarterly basis has been hovering around this like $14,000,000 to $15,000,000 quarterly rate for the last several quarters.

And seeing how the similar shortages or the effect of similar shortages are ameliorating somewhat. Do you think the franchise could return to generating like $16,000,000 17 million dollars anytime soon? And sort of what do you think it’s like the pathway or the strategy to get there?

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Yes. Thanks, Nans, for your question and appreciate you being on. We absolutely do anticipate growth. And the notion of $16,000,000 to $17,000,000 a quarter, we think is very feasible. Certainly, there has been some regression to the mean, so to speak, as the market has normalized.

But if we just keep up with market growth and just gain any share, we’ll be back into kind of that $16,000,000 to $17,000,000 range. So confident about that and equally confident about the pediatric products continuing to grow and get back significantly closer to where they were prior to some of the payer changes.

Nasr Rahman, Analyst, Maxim Group: Got it. That was helpful. And on the pediatric business, a few questions here. The first one is, so obviously you’re seeing growth again in the pete business, but were there any one time effects in the second quarter or any outside orders or any outside effects you saw in the second quarter? And in terms of products, which product did you see have the largest impact in the quarter?

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Yes, good question. No one time effects. This is organic. We can look at prescription growth that corresponds pretty well with our net revenue increases, some variability in gross to net sales, you know, just based on seasonality and various factors. So, yes, we’re seeing good old fashioned organic growth as a result of these initiatives that we put into place.

And in terms of the largest driver of that, the antihistamine franchise is the largest driver of the growth. In fact, when you look at carbinol, for example, it’s at the highest level of prescription since all the way back in Q2 of twenty twenty four. So essentially the better part of a year plus, the Carbinol franchise have not seen that. Pediatric multivitamins, we believe have certainly bottomed out. And while they haven’t grown back to where we’d like them to be, certainly think we’ve seen bottom and have started to kind of move back up.

But yes, Carbinol is driving most of that growth back.

Nasr Rahman, Analyst, Maxim Group: Got it. And on the continue on the P, I believe in your prepared remarks, you said you expanded coverage including state coverage. Could you talk a little bit about the dynamics in terms of Medicaid coverage in different states? And are you seeing, I guess, the same levels in reimbursement or different types of frictions in all the additional states you expand and how you’re working through that process?

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Yes, happy to. When we say we picked up coverage, we have picked it up on a pretty broad based sense, certainly commercial as well. And when you look at the state payers, the dynamics are distinct, but we don’t actively seek state level contracts. We have a national CMS rebate agreement as most companies have. And based on just some of the strategies we’ve employed, we’ve been able to get relatively broad based coverage.

Each state kind of makes their own decision in the context of what products they pick up, how they treat brands, how they monitor and manage those. And what I’ll say prior to the payer change, our Medicaid coverage was relatively limited and very concentrated in really just a couple of states where we concentrated most of our sales efforts. Following some of these changes that we put into place, we have multiplied the coverage in the number of states that have the NA histamine franchise now covered. And in terms of the rebates, in terms of the percentage reductions back to the states, they’re all the same essentially. So we don’t have any supplemental rebates in place with any particular state that drives the gross to nets down.

And so we’re able to actually have pretty healthy margins on that Medicaid reimbursed business. And the fact that we have diversified so much more we’re in so many more states now than two, we really are significantly or less reliant on any one state continuing to cover it at the same way. When I mean that when I say that, I mean covering it without say prior authorization, which is often the case with brands. And in a good handful of states, we have open coverage without any requirements for step edits or prior authorization. So excited about that.

We’re really just beginning to scratch the surface in some of the states where we hadn’t been before. As I mentioned in my prepared remarks, we’ve shifted some resources. We put sales representatives into states where again we picked up coverage, we’ve added the adenhistamine franchise into their, what we call, POA plan of action such that they are now responsible for promoting Carbinol and I think we’re at the early stages. Frankly, this growth is coming at a time when we’re really out of season. We’re not even out of winter yet.

So we expect good things as we head into the spring allergy season.

Nasr Rahman, Analyst, Maxim Group: Got it. That was helpful. During your prepared remarks, I believe you said you expect to have an additional $2,000,000 in cost savings. I just want to clarify that too. Where is that additional $2,000,000 coming from or is that $2,000,000 the same to extract previously?

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: No, we would expect that and Ryan, please jump in here, but we would expect that on top of what’s generally been realized and start to realize some of that here in this current quarter in March. So that’s $2,000,000 kind of on an annualized basis and that’s largely coming out of G and A. So really think of that as a quarter $500,000 on a quarterly basis kind of starting in and around this quarter and kind of going up from there. But Ryan, if you have anything to add to that, feel free to jump in.

Ryan Selhorn, Chief Financial Officer, Aytu BioPharma: Right. Now, this is basically the result of some of the actions that we’ve taken in this past quarter and in the second quarter with some additional headcounts from G and A and kind of slowing down some of the contracted services that we have. So that’s kind of where we’ll start seeing the benefit going forward into Q3 and Q4.

Nasr Rahman, Analyst, Maxim Group: Got it. And I guess if I could ask one last question. On the business development front, could you just provide more color on where you are in the process in terms of a potential tuck in or larger acquisition. I guess, like where are you guys in terms of talk and what have been the gaining factors to potentially closing a deal?

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Yes. What I’ll say, Nas, is in active discussions and pretty excited about some opportunities as we kind of take the next step with some of these parties. I’ll caveat that with deals take time and they’re unpredictable all the way to the eleventh hour and into signing day. You continue to say they’re never done until they’re done. But we are, I would say, in active discussions under CDA and certainly at the point of sort of modeling these opportunities.

And And what I’ll say further to that is, we’re looking at a cross section of opportunities across CNSpsychiatry and in pediatrics, understanding of course we touch both areas. We’re looking initially and most preferentially opportunities that we think we can secure with small or no upfronts. Those are difficult to sometimes pull off, but we’re optimistic that we may be able to do that. We obviously are looking at things that we think have good upside and will be accretive, of course. That having been said, we’re not in a position to take big dollars off the balance sheet to go pay big upfronts, but we want to be open minded for the right types of opportunities.

So we’re in active negotiation. So excited about what we have in our sites. I can’t say there’s anything imminent in terms of any kind of an announcement, but certainly at a point of bringing in internal resources to really start fulsome evaluation of these opportunities. Don’t want to put a timeline on it, hard to say exactly when that could happen, but happy to say that I think the environment for the types of things that we’re looking at is improving. And yes, we’re optimistic that maybe we can get something done here.

Nasr Rahman, Analyst, Maxim Group: Thanks for taking my questions. And once again, congratulations on the quarter.

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Thanks, Nas.

Conference Operator: Thank you.

Robert Blum, Investor Relations, Aytu BioPharma: Matthew, while we wait to see if there’s any further questions, we have just a couple of offline questions. I think that now it didn’t yet hit on Josh and Ryan. So I’ll just bring a couple of these up here. First off, any updates on some of the legal issues that were mentioned on some of the earlier

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: calls? Yes, thanks, Robert. I’m happy to say for the first time in a very long time that all of the shareholder litigation that would have started several years ago is now behind us. As was mentioned and foot noted in the 10 Q, both the Whitmer class action suit as well as the Revive investing case in which A2 was named as a nominal defendant, they’ve been resolved, one of which was really settled for some governance changes, which we’ve discussed in the past and payment of attorney’s fees. The most recent one, the Revive Investing case, went through a jury trial and was found in favor of the defendant.

And so that case has reached a final verdict pending any appeals, which we don’t think is realistic. So happy to say on that front that we are sort of finished with all those matters.

Robert Blum, Investor Relations, Aytu BioPharma: Okay, great. Ryan, perhaps this one is on your side and I think Nas touched on it briefly, but maybe just expand on in terms of a go forward expense level basis, you mentioned the additional 2,000,000 in savings, so maybe expand upon that to extrapolate what sort of the go forward expense level looks like?

Ryan Selhorn, Chief Financial Officer, Aytu BioPharma: Yes. Happy to do so. Yes, just to piggyback off of Nazzi’s question. Obviously, our management team is very focused on controlling the future operating expenses, especially those that don’t impact the top line revenue results. We believe we’ve finally completed all the material costs associated with our restructuring and optimization plans.

So going forward, I don’t anticipate any material additions to the restructuring expense line in our financials as we’ve had in the previous quarters. Additionally, with the final headcount reductions that we made last quarter, I do expect to see some additional benefits on our operating expense level in Q3 and Q4. To provide a little bit of perspective, we reduced net headcount by 12 individuals just at the tail end of the second quarter, which will definitely impact the future quarters going forward. Additionally, there’s been a few remaining contracts related to our previous pipeline that have been finalized in early Q3. So more savings there as well.

Hopefully that expands on kind of the overall savings. But I’m confident that the third and fourth quarter will kind of demonstrate a true optimized operating expense level that should allow us to grow the top line results without much incremental costs, especially at the G and A level.

Robert Blum, Investor Relations, Aytu BioPharma: Okay, very good. Fantastic, Ryan. Josh, it doesn’t appear as though we have any more questions on the live portion of the call. So, Josh, I guess I’ll turn it back over to you for any closing remarks.

Josh Disbrow, Chief Executive Officer, Aytu BioPharma: Great. Thanks, Robert. Thanks, Nas, for your questions and thanks to everyone for your participation on today’s call. Again, as always, and I’ll just reiterate, I thank the entire Aytu team for their hard work and all they’re doing to help us get in this position to help deliver for patients and for stockholders, reiterate the fact that I’m very proud of what we have accomplished, really excited about the future, particularly as some of these opportunities that I loosely referred to continue to sort of percolate out there. Thanks again for your participation on the call.

We look forward to sharing our results with you next quarter. Until that time, have a good evening and thank you again.

Conference Operator: Thank you. Everyone, this concludes today’s event. You may disconnect at this time and have a wonderful day. Thank you for your participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.